Fresenius SE & Co KGaA to Acquire Rhoen-Klinikum AG; Raises FY 2012 Guidance

Fresenius SE & Co. KGaA announced its intention to make a voluntary public takeover offer to Rhoen-Klinikum AG shareholders of EUR 22.50 per share in cash. The total purchase price for all outstanding shares in Rhoen-Klinikum AG is approximately EUR 3.1 billion. The offer, representing a premium of 52% on Rhoen-Klinikum AG's closing share price on April 25, 2012 and of 53% on the share's volume weighted average trading price over the last three months (XETRA), is contingent upon a minimum acceptance threshold of 90% plus one share of Rhoen-Klinikum AG's share capital at the end of the offer period and on antitrust approval. Furthermore, the Company announced that it has raised its fiscal year 2012 guidance and expects net income growth of 12% to 15% in constant currency. Previously, the Company expected net income growth of 8% to 11%. Sales growth of 10% to 13% in constant currency is projected at the upper end of the targeted range. For the fiscal year 2011 the Company reported net income of EUR 770 million and sales of EUR 16,522 million. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2012 revenue of EUR 18,773.86 million and fiscal year 2012 net income of EUR 893.89 million.